Barcelona and Hansi Flick face one of the most difficult weeks of their season, with a Champions League clash against PSG and El Clasico on the horizon.
Former Premier League striker Troy Deeney has made a bold prediction ahead of Sunday's El Clasico.
He has insisted that Real Madrid have virtually no chance of defeating Hansi Flick's Barcelona, given the two sides' current form.
As quoted by Mundo Deportivo, Deeney made the comments during an appearance on CBS Sports' Golazo programme.
He questioned Madrid's collective strength and ability to play as a team despite their recent 4-1 victory over Sevilla.

#Barcelona #hansi #made #former

SCHD yields 3.82% with principal at risk daily, while VIG targets dividend growers built to outpace inflation over a long horizon.
Qualified dividends face tax rates between 0% and 20%, compared to up to 37% for savings interest, a gap that can exceed the difference in yields.
High-yield savings protect dollars with FDIC coverage up to $250,000, but rates float and can drop the moment the Fed cuts.
Just released. Our ****** ysts combed the entire stock market and named the ten best stocks to buy right now. The report is free. Enter your email and see if any of your stocks made the cut.
High-yield savings rates were holding steady on Oct. 8, 2026, according to Forbes. They are holding at a higher level than a month ago because the Federal Reserve raised its target range in September. Online banks use the federal funds rate's upper bound to price their accounts, and it moved from 3.75% to 4.00% on Sept. 16, 2026 and was unchanged as of Oct. 7. On that date the 4-week Treasury bill, the closest market benchmark for overnight cash, yielded 3.95%. Typical banks pay much less. The FDIC national average 12-month CD rate was 1.73% as of Sept. 1, 2026, and top online banks routinely pay a multiple of that average. Rates differ from bank to bank, so the posted APY at your own bank is the number that applies to you.

#savings #sept

Kim Kardashian is giving fans another glimpse into her latest fashion collaboration. The mogul shared a new video documenting a fitting for her upcoming capsule collection. Fans see her trying on pieces inside a dimly lit studio alongside the collection's designer. Naturally, the highlight was her strapless sequined minidress, a bold bronze-gold number that perfectly matched the shoot's moody, intimate mood.
In the clip, Kim Kardashian stands in a dressing room lined with clothing racks, trying on the finished look in real time. The post was captioned, "A collaboration built on shared language: the body as material."
For the fitting, Kardashian wore a strapless, sequined micro minidress in a warm bronze-gold tone. The fitted, bandage-style design featured horizontal ribbing that wrapped tightly around her torso. It boasted a sweetheart neckline, a mini-length hem, and an all-over metallic sheen. The dress highlighted her famous curves while fitting right into the collection's aesthetic.
Kardashian kept the rest of the look stripped back, skipping jewelry and accessories altogether. With nothing else competing for attention, the dress itself became the clear focal point of the clip. She wore her dark hair sleek and straight, leaving it loose to frame her face throughout the fitting. Her makeup stayed soft and natural, keeping the focus on the dress rather than a full glam beauty look. For Kardashian, it's a reminder that when it comes to this particular launch, the body truly is the material.
The strapless silhouette is free of accessories and distractions, allowing the dress's clinging shape to do all the talking. The clip comes as the capsule officially hits shelves, with the post confirming fans can now purchase the collection. With the capsule now live, the bronze-gold minidress offers an early preview of just how body-conscious the full collection is likely to run. The post offered fans a rawer, closer look at the collaboration than its earlier campaign imagery provided.

#kardashian #fans #capsule #minidress

WASHINGTON (AP) — The U.S. military is dispatching roughly 9,000 troops aboard a group of ships to the Middle East, a U.S. official said Thursday. The bolstering of the American military presence comes as President Donald Trump warned anew that new strikes against Iran could be on the horizon.
The troop movement, which includes a third aircraft carrier, underscores the rapidly evolving dynamic of Trump's war against Iran as he ponders his next move, with midterm elections in the United States looming large and new signs that the nature of the conflict may be becoming more complex.
Trump has threatened that a post-midterm election escalation — despite his initial promises to Americans of a campaign that would last a matter of weeks — remains a viable option. Further complicating matters, Trump told reporters Thursday that early indications suggest that Iran is linked to the FlyDubai co-pilot who stabbed his captain and tried to crash an Israel-bound flight on Wednesday.
In an exchange with reporters at the White House, Trump raised the connection when asked by a reporter if there were any links between the pilot behind the attack and Tehran.
"I would say the answer, based on what I'm hearing, is 'yes,' but we're working on it right now," Trump said, without offering details.

#military #reporters #washington #middle

Miranda Kerr was a sight to behold in a Stella McCartney cutout dress as she strutted down the runway at PFW. The Australian supermodel returned to the runway after a decade-long hiatus, embodying elegance as always. Photos and videos of her from the September 30 show have taken over the internet.
At PFW, Miranda Kerr turned heads with her return to the runway after a decade in a stunning Stella McCartney cutout dress. The ethereal sage green piece featured a padded, cap-sleeved bodice designed with strong, architectural shoulders that tapered sharply into fine vertical pleating across the chest. The bodice converged at the center of the waist into a knot detail, framing symmetrical side cutouts that revealed her midriff.
Furthermore, the back revealed a low-cut design with a gathered detail across the lower shoulder blades. Extending from the central waist knot was a floor-sweeping sash that flowed down the front of the skirt, pooling softly over her feet as she walked.
The skirt also featured horizontal ruching around the hips. It hugged her silhouette before falling into a fluid, straight column shape. The piece blended sculptural tailoring with soft, fluid draping.
Kerr paired the dress with metallic silver wedge sandals featuring transparent straps. The footwear matched the light color palette while elevating her frame. In her hand, she carried a textured, snake-print hard-shell clutch. Meanwhile, her beauty styling leaned into minimalist glamor to complement the serene tones of the dress.

#miranda #stella #mccartney #piece

Charles Schwab is holding a neutral stance on equities. The firm favors commodities over stocks and bonds, according to chief investment strategist Liz Ann Sonders.
Sonders made the comments in a recent interview, pushing back on what she called "cookie-cutter" portfolio advice. She said allocation should hinge on each investor's time horizon, risk tolerance, need for income, and overall goals.
"It actually drives me a little crazy when people give a cookie-cutter answer to that," Sonders said. "There's no one ***** et allocation that makes sense right now."
https://www.youtube.com/wa...
Schwab oversees $13.4 trillion in client ***** ets, and Sonders pointed to that scale as proof there is no single right answer for every client.

#sonders #cutter #answer #h5jfl8lawe

Estes Express Lines is investing nearly $56 million to expand its cross-border and offshore freight network, including terminals, equipment and capacity serving Canada, Mexico, Alaska, Hawaii and Puerto Rico.
Alex Peebles, senior director of offshore and international at Estes, said the privately held, family-owned carrier is taking a longer view of the freight market rather than allowing current conditions to dictate its investment strategy.
"We're really looking at all of these investments from a long-term horizon and viewpoint perspective and one that's going to help accommodate growth and capacity into all the offshore international markets that we service," Peebles told FreightWaves.
Estes, which is celebrating its 95th anniversary this year, is North America's largest privately held less-than-truckload (LTL) freight transportation provider. The company operates a network of over 300 terminals and service centers across the U.S., Puerto Rico, Alaska, Hawaii with coverage extending to Canada, Mexico and the Caribbean
Peebles said the company's ownership structure gives it flexibility to move quickly when real estate and equipment opportunities arise.

#rico

MercadoLibre, Inc. (NASDAQ:MELI) priced $1 billion of senior unsecured notes on September 9, 2026, with settlement scheduled for September 14 and maturity on September 14, 2036. As of September 10, the transaction had not settled.
The notes carry a 5.85% coupon, with proceeds intended for general corporate purposes. Once settled, they would require $58.5 million in annual coupon payments on the full principal outstanding, alongside repayment of $1 billion at maturity.
Management retains discretion over deployment. Logistics, payments, credit and commerce represent potential uses within the business, rather than disclosed allocations of this particular offering.
Ten-year funding can better match investments whose benefits emerge over several years. Logistics facilities need time to attract shipment volume, while financial-services products require investment in technology, customer acquisition and risk management before reaching scale.
For MercadoLibre, Inc. (NASDAQ:MELI), that longer horizon could reduce dependence on repeated short-term refinancing. A fixed coupon also makes contractual dollar interest payments more predictable if market borrowing rates rise.

#payments

Broyhill **** et Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index's 15.1% and the MSCI ACWI Value Index's 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The letter highlights that a significant portion of the shortfall occurred in April due to market dynamics and geopolitical events, with tech, particularly semiconductors, driving recent gains. Broyhill notes its lack of direct semiconductor exposure but acknowledges potential interest in the sector if opportunities arise, maintaining its investment philosophy focused on capital protection in fragile market conditions. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Broyhill **** et Management highlighted First Citizens BancShares, Inc. (NASDAQ:FCNCA). First Citizens BancShares, Inc. (NASDAQ:FCNCA) operates as the holding company for First-Citizens Bank & Trust Company, providing retail and commercial banking services. On September 14, 2026, First Citizens BancShares, Inc. (NASDAQ:FCNCA) closed at $2,173.88 per share. Over the past month, First Citizens BancShares, Inc. (NASDAQ:FCNCA) declined 1.03%, but its shares are up 17.10% over the past year. First Citizens BancShares, Inc. (NASDAQ:FCNCA) has a market capitalization of $24.55 billion, and its stock has traded within a 52-week range of $1,623.76 to $2,296.30.
Broyhill **** et Management stated the following regarding First Citizens BancShares, Inc. (NASDAQ:FCNCA) in its Q2 2026 investor letter:
"First Citizens BancShares, Inc. (NASDAQ:FCNCA), initiated in June, is a well-run company which we believe to be undervalued and with catalysts on the horizon. The company has retired almost 20% of its Class A shares since July 2024, and inside its roughly $25 billion market capitalization sits a rail leasing fleet of approximately 128,000 cars valued by the market at bank multiples. Management has proven themselves highly competent and highly aligned with shareholders, with the Holding family in key executive positions, owning over 20% of the economics and controlling roughly half the vote through their Class B shares. Much of what we are waiting on has a date attached to it: two separations have completed, and Masco and First Citizens are retiring shares at a pace that improves per-share value whether or not the multiples change."

#fcnca #market

Broyhill ******* et Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index's 15.1% and the MSCI ACWI Value Index's 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The letter highlights that a significant portion of the shortfall occurred in April due to market dynamics and geopolitical events, with tech, particularly semiconductors, driving recent gains. Broyhill notes its lack of direct semiconductor exposure but acknowledges potential interest in the sector if opportunities arise, maintaining its investment philosophy focused on capital protection in fragile market conditions. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Broyhill ******* et Management highlighted First Citizens BancShares, Inc. (NASDAQ:FCNCA). First Citizens BancShares, Inc. (NASDAQ:FCNCA) operates as the holding company for First-Citizens Bank & Trust Company, providing retail and commercial banking services. On September 14, 2026, First Citizens BancShares, Inc. (NASDAQ:FCNCA) closed at $2,173.88 per share. Over the past month, First Citizens BancShares, Inc. (NASDAQ:FCNCA) declined 1.03%, but its shares are up 17.10% over the past year. First Citizens BancShares, Inc. (NASDAQ:FCNCA) has a market capitalization of $24.55 billion, and its stock has traded within a 52-week range of $1,623.76 to $2,296.30.
Broyhill ******* et Management stated the following regarding First Citizens BancShares, Inc. (NASDAQ:FCNCA) in its Q2 2026 investor letter:
"First Citizens BancShares, Inc. (NASDAQ:FCNCA), initiated in June, is a well-run company which we believe to be undervalued and with catalysts on the horizon. The company has retired almost 20% of its Class A shares since July 2024, and inside its roughly $25 billion market capitalization sits a rail leasing fleet of approximately 128,000 cars valued by the market at bank multiples. Management has proven themselves highly competent and highly aligned with shareholders, with the Holding family in key executive positions, owning over 20% of the economics and controlling roughly half the vote through their Class B shares. Much of what we are waiting on has a date attached to it: two separations have completed, and Masco and First Citizens are retiring shares at a pace that improves per-share value whether or not the multiples change."

#first #fcnca

Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. And since Amgen's late-stage ******* et olpasiran relies on the same biological premise, investors immediately marked down Amgen on the negative read-through.
The result strikes at a premise rather than at a product. Pelacarsenhad lowered Lp(a) by roughly 80% in earlier studies. In Lp(a)HORIZON, Novartis said pelacarsen substantially lowered Lp(a), but it still failed to reduce the composite of cardiovascular death, heart attack, stroke, and urgent revascularization. It still could not reduce the composite of cardiovascular death, heart attack, stroke, and urgent revascularization. And now the entire hypothesis that lowering Lp(a), a genetic cardiovascular risk factor, actually cuts events, is being directly challenged. Olpasiran is built on the same hypothesis, leading to the repricing of odds as soon as pelacarsen's data were out.
Amgen's olpasiran, an siRNA, lowered Lp(a) by more than 95% at certain doses in Phase 2, compared with reductions of roughly 80% for pelacarsen in earlier studies. The bull case is that this deeper reduction could help olpasiran deliver better cardiovascular outcomes.. The bull case is that this 15% will help Amgen to make a deeper cut and deliver results. While biologically possible, the Lp(a)HORIZON trial provided no evidence that a clinical threshold exists above an 80% reduction. The topline Phase 3 announcement did not establish that deeper Lp(a) lowering would have produced a cardiovascular benefit. It is therefore appropriate to say that the miss lowered olpasiran's probability of success rather than pretending it is irrelevant. Eli Lilly's lepodisiran is running the same deep-reduction experiment, so the hypothesis will be tested with or without Amgen.
Amgen is not an Lp(a) pure-play. MariTide in obesity, Repatha in cholesterol, and Tezspire in asthma drive more value for the company, and this diversification creates a cushion for the stock, although the selloff ultimately became much larger than the initial 5% after-hours reaction. Positioning has stayed calm since the beginning of 2026. Insider Monkey data shows 66 hedge funds held AMGN in the second quarter of 2026, up slightly from 65 in the first. Short interest, on the other hand, sits at just 2.4% of float, reflecting minimal bets against the stock in the market.

#horizon #pelacarsen

If you are looking for yield today, rising interest rates have increased your options. For example, the 30-year Treasury bond's yield is around 5.3% as of this writing. By comparison, the S&P 500 index (SNPINDEX: ^GSPC) is only yielding around 1%. But there are still two big reasons why investors may want to buy a high-yield dividend stock like Coca-Cola (NYSE: KO), even though its 2.4% yield isn't even close to the 30-year Treasury yield.
A bond is an agreement between the lender and the borrower. The lender provides a fixed amount of cash, while the borrower pays interest at a fixed rate until the loan matures. When the loan matures, the borrower repays the bond's principal. Everything is fixed, and both the value of the interest collected and the bond's principal are slowly eroded by inflation. It doesn't matter that 30-year Treasuries are considered safe because they are backed by the U.S. government. The big inflation risk is still the same.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
If you have a short investment time horizon, inflation may not be a big issue for you. In which case, the 5.3% yield of a 30-year Treasury would probably be more attractive than Coca-Cola's 2.4% yield. However, if you have a long time horizon, Coca-Cola's yield comes with something that a Treasury doesn't: Growth.
Coca-Cola is one of the world's largest consumer staples companies. It has an incredible history of growth, highlighted by 64 annual dividend increases. That makes the company a Dividend King. But think about that for a second, you can collect 30 years of the same income from a bond or 30 years of increasing income from Coca-Cola. Since the start of 1996, roughly 30 years ago, the company's dividend has increased by nearly 750%. That dividend growth was driven by the company's growth, which also led to an over 300% increase in the stock price. If you hold a bond to maturity, all you get back is the principal.

#coca

Matchday 27 continued this Saturday (12) with six more games.
After the "crazy" 3-3 draw between Coritiba and Athletico-PR in the opening match of the round last Friday (11), the "rain of goals" continued in the Brasileirão.
The day began with Atlético-MG's solid 3-1 win over Fluminense in Belo Horizonte.
Both the Minas Gerais side and the Rio de Janeiro team fielded reserve/mixed lineups because of their continental deciders next week.
Galo need to overturn a 2-0 deficit at home against Santos in the Conmebol Sudamericana quarter-finals, while the Laranjeiras Tricolor travel to Argentina to face Platense holding a 2-0 advantage in the Libertadores quarter-finals.

#quarter #Friday

It's the middle of September and Pat Kelsey and company are still active in the transfer portal.
LJ Wells, a 6'8 power forward who played the last four seasons at Northern Kentucky, has committed to play for Louisville in 2026-27. Wells is the namesake plaintiff in the ongoing Wells vs. NCAA case in Jefferson County Circuit Court that earned a fifth-year of eligibility for players like Wells, D'Angelo Hutchinson, Jabari Mack, and Missouri hooper Mark Mitchell.
Wells started all 33 games for the Norse last season, posting career-best averages of 15.0 points and 7.3 rebounds per game. He also earned All-Horizon Tournament Team honors after averaging 22.3 points, 8.7 rebounds and 2.7 ***** ists while helping NKU to the Horizon League semis, where they fell to eventual champion Wright State.
It feels weird to be adding players like this, especially when you can't be 100 percent sure if they're even going to be able to play this winter, but this is a nice depth add at a position where U of L could definitely use some additional depth.
Welcome aboard, LJ.

#last

DETROIT — His college career unfrozen by a judge, Orlando Lovejoy is headed to the frozen tundra.
Lovejoy, who starred for Detroit Mercy men's basketball the last two seasons, has committed to fellow Horizon League program Green Bay for his fifth and final season of eligibility.
Lovejoy was among hundreds of college athletes from the high-school class of 2022 who were granted a fifth season of eligibility through temporary restraining orders from judges across the country. The NCAA recently announced a five-year eligibility window, starting with the high-school class of 2023.
Lovejoy, 23, was one of the top point guards in the Horizon League the last two seasons, and in 2025-26, he was first-team all-league as he led the **** ans to within a whisker of the league tournament championship and an appearance in the NCAA Tournament. Lovejoy, a Detroit native, started all 31 games for Detroit Mercy in 2025-26, and was top 10 in the league in scoring (15.8 points), **** ists (3.7) and steals (1.6). He made free throws at an 89.2% clip.
Lovejoy spent his first two college seasons at Eastern Michigan, before transferring to Detroit Mercy after the school hired Mark Montgomery as head coach. He contemplated transferring after his first season at Detroit Mercy to capitalize on NIL opportunities, but he ultimately returned to the **** ans and led them to the Horizon League championship game, in which they led much of the game before falling to Wright State, 66-63.

#seasons

Horizon Technology Finance Corp., an affiliate of Monroe Capital, on September 10 said that the RoHo Capital Opportunity Fund LLC, a joint venture formed by Horizon and CR Financial Holdings, Inc., the holding company for Roth Capital Partners, LLC, has provided a $20-million senior credit facility to NeoVolta, Inc., with the ability to increase the facility to $30 million upon mutual agreement. An initial $20 million was funded at closing to support NeoVolta's continued growth.NeoVolta is an energy technology company focused on developing and manufacturing domestic battery energy storage systems (BESS). Together with its joint venture partner LONGi, NeoVolta is developing a 210,600-square-foot manufacturing facility in Pendergrass, Georgia, to produce BESS systems designed to meet U.S. domestic content and supply-chain requirements. The facility is expected to have an initial annual production capacity of up to 2 GWh, with the potential to scale to 8 GWh over time."Providing growth capital to innovative companies operating in attractive, high-growth markets is a core focus of RoHo's investment strategy," said Paul Seitz, chief investment officer of Horizon. "Formed by Horizon and Roth Capital, RoHo pairs Horizon's venture lending and structuring expertise with Roth's deep public markets relationships to deliver flexible growth capital to small- and micro-cap public companies. We are pleased to support NeoVolta's growth plans with a tailored financing solution and look forward to continuing to deploy capital through RoHo in support of innovative public companies pursuing significant market opportunities.""Horizon and Roth Capital bring valuable experience and a collaborative approach as we advance NeoVolta's domestic battery energy storage systems manufacturing platform," said Ardes Johnson, CEO of NeoVolta. "As we ramp our Georgia facility and pursue larger commercial and utility-scale opportunities, this relationship supports our ability to execute on our long-term growth strategy."Horizon Technology Finance Corp. is a specialty finance company that provides capital in the form of secured loans to venture capital and private equity-backed companies and publicly traded companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio's return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located throughout the U.S.Monroe Capital is a premier ****** et management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, opportunistic, structured credit, real estate and equity.CR Financial Holdings, Inc., is a private hol

Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease.
Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in the overall population. The endpoint combined cardiovascular death, nonfatal heart attack, nonfatal stroke, and urgent coronary revascularization requiring hospitalization. Complete results have not yet been presented.
Royalty Pharma plc (NASDAQ:RPRX) provided Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) with $500 million in January 2023. The transaction allocated $150 million to pelacarsen royalties and $350 million to Spinraza royalties. The clinical failure shifts the financial focus from uncertain pelacarsen upside to recovery through Spinraza.
Royalty Pharma plc (NASDAQ:RPRX) acquired 25% of the Spinraza royalties received by Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) through 2027. That share increases to 45% in 2028 on Spinraza annual sales of up to $1.5 billion.
Following the HORIZON result, the Spinraza interest will revert after aggregate payments to Royalty Pharma plc (NASDAQ:RPRX) reach $550 million, equal to 1.1 times the original funding. Management expects the structure to recover the entire investment and generate a modest positive return despite the clinical failure.

#royalty #pharma #cardiovascular #horizon

The Tennessee **** ans made the first somewhat surprising pick of the 2026 NFL Draft when they selected former Ohio State wide receiver Carnell Tate with the number four overall pick. With his first NFL game on the horizon, CBS Sports' Ryan Wilson believes he was worth the fourth overall pick for the **** ans.
Tate was drafted with the expectation that he can become a foundational piece of the offense and a long-term number one target for second-year quarterback Cam Ward. That might be a lot to ask from a rookie, but everything about the situation suggests the **** ans had a plan.
The biggest question surrounding the **** ans' selection was whether Tate's talent will eventually justify taking him fourth overall. Including Tate, only five wide receivers (six if you include Travis Hunter) have been selected in the top five of the NFL Draft since 2015.
Excluding Jacksonville Jaguars WR/CB Travis Hunter, former **** ans WR Corey Davis had the worst rookie season of those top five selections with 375 yards and 0 touchdowns. So, it made sense why **** ans fans, specifically, may have had concerns about the Tate selection.
However, a strong training camp has many anticipating his NFL regular-season debut. Tate doesn't need to immediately become one of the best receivers in the NFL for the pick to be successful, but Tennessee needs to see enough flashes to believe they have found a long-term offensive cornerstone.

#tate #draft

As we head into Gameweek 4 of the 2026/27 Fantasy Premier League season, making the right armband choice is critical for solidifying early-season rank gains.
With prime fixtures on the horizon – including heavy hitters facing vulnerable defenses and high-flying budget **** ets continuing to shock the league – selecting the right captain can make or break your weekend.
Here is a breakdown of the top GW4 FPL captaincy pick options to help you make the ultimate decision.
Despite playing away at Old Trafford in the Manchester derby, Erling Haaland remains the undisputed premier option among game week 4 FPL captain picks.
Manchester United's backline has looked shaky to start the campaign, surrendering six goals in their opening three league matches.

#league #captain

Former First Lady Michelle Obama brought striped style to the 2026 U.S. Open women's singles semifinals on Thursday night at the USTA Billie Jean King National Tennis Center in New York City.
Michelle Obama
Obama sported a red, white and dark-striped dress for the Grand Slam tennis tournament. The quasi-patriotic palette got contemporary edge from faded lines running through the red and dark navy stripes, which shifted between vertical and horizontal directions.
More from WWD
Gabrielle Union Brings Out Ferragamo's Trendiest Suede Mules to the 2026 U.S. Open

#former

On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints at week 24 in patients with eosinophilic esophagitis. These benefits were sustained through week 52 across both tested doses, accompanied by a safety profile consistent with its approved indications. While CROSSING highlights their joint R&D success, a closer look at their standalone financial performance reveals distinct growth trajectories.
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.

#revenue #astrazeneca #increased #products

On August 11, Humana Inc. (NYSE:HUM) announced that its Medicaid plan, Humana Healthy Horizons in Indiana, is collaborating with HealthStream, Inc. (NASDAQ:HSTM). The partnership expands access to workforce training for caregivers, aiming to recruit and retain talent in rural and underserved communities. While one provides healthcare coverage and the other builds the software to train healthcare workers, both companies are capitalizing on the industry's critical focus: solving caregiving shortages and optimizing healthcare delivery.
HealthStream emerges as the operationally cleaner, higher-growth performer, while Humana continues to navigate a more complex transition marked by regulatory and profitability pressures. Humana Inc. (NYSE:HUM) reported Q2 2026 GAAP EPS of $5.73 and adjusted EPS of $7.61, with an Insurance segment GAAP benefit ratio of 91.2%. The company reaffirmed its full-year adjusted EPS guidance of at least $9.00 but lowered its FY 2026 GAAP EPS forecast to at least $6.52 from $8.36, reflecting non-cash adjustments and value creation charges. Although individual Medicare Advantage membership is expected to grow approximately 25% in 2026, lower Star Ratings remain a significant drag on profitability.
HealthStream, Inc. (NASDAQ:HSTM), meanwhile, delivered record Q2 2026 results, with revenue rising 12.5% year over year to $83.7 million. Operating income increased 41.4% to $8.3 million, while net income climbed 23.8% to $6.7 million, or $0.23 per diluted share. Adjusted EBITDA also increased 16.9% to $20.6 million. The company's debt-free balance sheet, supported by $66.7 million in cash and cash equivalents, further strengthens its financial flexibility. While Humana operates at substantially greater scale, HealthStream is demonstrating stronger operational leverage, margin expansion, and balance sheet flexibility.
Humana's bull case is supported by strong Medicare Advantage membership growth, with the company targeting a 25% increase in 2026, alongside strategic expansion of its CenterWell primary care business and state Medicaid footprint, including its recent Illinois win. These initiatives could strengthen its long-term recovery and expand its addressable market. However, the bear case centers on elevated medical benefit ratios, which reached 91.2% in Q2, as well as regulatory pressures in Medicaid and continued Medicare Star Ratings headwinds. These factors could further squeeze margins and weigh on net earnings.

#healthcare #year

CVS Health (NYSE: CVS) dealt with significant headwinds after the COVID-19 pandemic. The company's financial results suffered as sales of coronavirus-related products (such as diagnostic tests) declined, while expenses in its insurance business rose substantially, resulting in lower profits and margins. However, CVS Health has done a good job of addressing those problems, and the stock has rebounded. Shares are up 31% over the past 12 months. Wall Street thinks there may be even more upside on the horizon. CVS Health's average price target is $116.04 (according to Yahoo! Finance), implying a meaningful 20% upside from current levels. Is now a great time to buy the stock?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Over the past 18 months (or so), CVS Health has implemented several initiatives that have helped improve its business. For instance, the company closed dozens of stores, many of which were unprofitable. The pharmacy chain specialist also scaled back its insurance division, notably by exiting the Affordable Care Act marketplace. The results have been pretty impressive. Consider the company's second-quarter results. CVS Health's revenue increased by a healthy 7.3% year over year to $106.1 billion.
Adjusted earnings per share were $2.58, 42.5% higher than the year-ago period. Note the improvement in CVS Health's healthcare benefits segment, which offers health insurance services. Operating expenses as a percentage of revenue declined slightly to 12.4%, down from 12.5% in the prior-year quarter, even as revenue grew 3.5% year over year. And operating margins within this unit came in at 5.8%, up from the 2.8% reported in the year-ago period. Also, CVS Health's medical benefits ratio -- the percentage of insurance premiums the company spent on medical care (the lower the better) -- declined to 87.4% in the second quarter, down from 89.9% in Q2 2025.
CVS Health also increased its guidance for the full fiscal year 2026. The company now expects its adjusted EPS to fall between $7.90 and $8.10, up from its previous range of between $7.30 to $7.50. The company is also now projecting cash flow from operations of at least $11.5 billion, up from the previous lower bound of $9.5 billion. These are signs of a much-improved business.

#insurance

Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Gold (GC=F) December futures opened at $4,399 per troy ounce on Wednesday, September 9, 2026, down 0.9% from Tuesday's closing price. Gold moved back higher in early trading this morning to $4,438.20 per troy ounce as of 6:34 a.m. ET.
Exactly one week ago, our headline here was "Gold slips further as military actions escalate in Iran." And that's exactly the headline news yet again.
Oil prices (BZ=F) are currently over $100 a barrel, as gold opens at its lowest value in a week, following reports that the U.S. military destroyed five more Iranian oil tankers in response to Iranian attacks on U.S. warships:
U.S. Central Command (Centcom) announced late on Tuesday that American forces had destroyed five Iranian crude oil carriers, once again claiming that it was in response to the IRGC targeting a U.S. Navy warship with ballistic missiles. Four of the carriers, M/T Kaviz, M/T Charminar, M/T Horizon 1, and M/T Riesco, were destroyed in the Gulf of Oman. One of the carriers, M/T Derya, was struck near Kharg Island.

#Gold #military

Northern Kentucky University's men's basketball program announced its full slate of non-conference games with the Norse set to host five games at Truist Arena.
Northern Kentucky opens the 2026-27 season in Sioux Falls, South Dakota, taking on UTEP as part of the Field of 68 Opening Day Marathon. The Norse will stay in the Mount Rushmore State for a matchup with South Dakota on Nov. 4. As previously announced, NKU then heads to College Station, taking on Texas A&M on Nov. 6. It marks the first time the Norse have played Texas A&M since the 2017-18 campaign. Northern Kentucky wraps up its four-game road trip to open the season at Chaifetz Arena, where they'll take on Saint Louis on Nov. 10.
Both Texas A&M and Saint Louis reached the second round of the NCAA Tournament last season.
Then, the Norse start a four-game homestand leading into Thanksgiving, opening their home schedule on Nov. 14 against Central Michigan. Last season, NKU beat the Chippewas by 24 in Mount Pleasant. Northern Kentucky will then host Georgia Southern on Nov. 23 and Bellarmine on Nov. 25 as part of a a multi-team event with those teams playing each other at Truist Arena Nov. 24. Northern Kentucky's matchup with Georgia Southern will be the first in program history, while this season's matchup vs. Bellarmine marks the 80th all-time, with the Norse leading the series 45-34.
NKU has four out-of-conference games in December, taking on Defiance on Dec. 8, before facing South Carolina State on Dec. 11, both at Truist Arena. The Norse wrap up their non-Horizon League schedule by taking on ETSU in Johnson City on Dec. 15, before traveling up to Cambridge, Massachusetts, to take on Harvard on Dec. 20. It'll mark the first time that the Norse and Crimson have faced off, while the Norse traveled to ETSU last season.

#taking #texas

The summer window may have just closed, but Barcelona are already planning for January, with a significant financial decision looming on the horizon.
The club have approximately €60 million available in their Financial Fair Play allocation, giving them room to manoeuvre in the winter market should they choose to.
However, that money could also serve a very different purpose, particularly for the season ahead.
Barcelona bosses have a decision to make. (Photo by Alex Caparros/Getty Images)
According to Diario SPORT, Barcelona face a clear choice with their available FFP funds.

#caparros

On a cold November morning, designer Isaac Mizrahi gets up, leaves his apartment, and trudges to the corner newsstand to pick up a copy of Women's Wear Daily. It's the day after Mizrahi's Spring/Summer 1994 show, and the ink on the reviews is still wet. Reading from the pages, he quotes, "'His usually great color sense failed him, his fabric sense failed him, and certainly, his sense of how a modern woman dresses after 8 p.m. failed him." The verdict is withering. Mizrahi, one of the great artists of '90s ready-to-wear fashion, has been tossed out. Disgraced. Lightly "cancelled," as some might call it these days.
Douglas Keeve's sublime 1995 documentary, "Unzipped," follows Mizrahi in the aftermath of a train wreck, piecing his reputation back together with his next collection, attempting to make something beautiful from the rubble. We find Mizrahi's world in grayscale, drained of color in the wake of critical and cultural failure. Then, the opening notes of Sandra Bernhard's 1994 cover of Sylvester's "You Make Me Feel (Mighty Real)" cue the pigmentation, cascading over bright images of models in fittings, garments hanging from racks, and plenty of DayGlo faux furs. In her version, Bernhard alters the lyrics to pay tribute to Sylvester, whose untimely death left an immense legacy. "Sylvester, sister," Bernhard coos, "You were so beautiful, you were so fragile, you were so . . . real."
But just before Bernhard finishes the word, the song fades to silence, as if to say that realness — genuine authenticity in your life and work, at the cost of criticism — will always be snuffed out before it can be fully appreciated. That is the price of beauty. What is up must always come down.
(Janus Films) Isaac Mizrahi in "Unzipped"
After years in cinematic obscurity — the film hasn't been readily available outside of the eBay market in decades — "Unzipped" will return to theaters later this month, with a loving 4K restoration from Janus Films, just as another fashion-world controversy is heating up. Earlier this week, the Metropolitan Museum of Art declared it would no longer proceed with its Costume Institute's upcoming exhibition honoring John Galliano, scheduled to debut next year. When the scrapped "John Galliano: Horizons" was announced in July, the exhibition was immediately met with an outpouring of criticism. Detractors accused the museum of being tone deaf, citing a 2011 video of Galliano going on a drunken antisemitic and racist rant at a Paris bar, for which Galliano was promptly ousted from his spot as creative director at Dior. Following the video surfacing, Galliano apologized, went to rehab, and, over the last few years, experienced a brand resurgence that some would call a whitewashing.

#mizrahi #bernhard #sense

John Galliano has canceled his Metropolitan Museum of Art exhibit, saying in a statement shared Monday (Aug. 31) that he remains "fully accountable for the pain caused by my words in the past."
In the statement, which comes amid mounting criticism against the designer, Galliano expressed gratitude to Anna Wintour and others involved with staging the exhibit, but conceded that the planned project should not move forward.
"After much reflection and discussion with all those involved, I have decided, with great sadness, that it is best for the exhibition not to take place at this time," Galliano said Monday, in part. "I remain fully accountable for the pain caused by my words in the past, particularly the hurt I caused to the Jewish and Asian communities, and I remain deeply sorry. I understand that meaningful atonement is not achieved through an exhibition, institutional recognition, or a single public gesture. It is a continuing responsibility, demonstrated through listening, learning, and one's conduct over time."
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.
The planned exhibition, ******* led John Galliano: Horizons, had previously been slated to open in May of next year. In addition to Galliano's personal statement, Max Hollein, who serves as director and CEO of the Metropolitan Museum of Art, also shared a confirmation of the cancelation.

#galliano

Ameresco insiders have been buying into a steep decline instead of waiting for the chart to improve. Form 4 filings show open-market purchases of roughly $1.9 million since August 7, including about $738,000 over the latest one-week sequence. CEO George Sakellaris accounted for approximately $574,000 across several purchases. Directors Brian ***** , Jennifer Miller, and Joseph Sutton also bought shares of Ameresco, Inc. (NYSE:AMRC). The cluster spread the bullish signal across four insiders rather than one executive.
The timing is interesting because the stock had fallen about 28% over six months. Ameresco develops energy infrastructure, including efficiency projects, renewable ***** ets, battery storage, and power systems that can support data centers. Its opportunity is not to predict which AI model wins. It is to help customers build the electricity and resilience those models require. Second-quarter revenue rose 9.1% to $515.5 million, showing that the operating business was still expanding during the selloff.
Insider buying is a useful signal, but it is not a guarantee. Executives may have long time horizons, personal tax considerations, or confidence that does not translate into near-term returns. Ameresco's projects carry construction, financing, customer-concentration, and execution risk. Diluted EPS of $0.18 fell 25% year over year in Q2, demonstrating that higher revenue does not automatically deliver better profitability. Large AI-related power awards can also produce uneven working-capital needs before cash arrives.
The hedge-fund picture was weaker than the insider activity. Insider Monkey tracked 17 hedge funds holding Ameresco, Inc. (NYSE:AMRC) in Q2, down from 22 in Q1. Millennium Management sharply increased its position by 490% to 1,487,282 shares, however, making the quarter more nuanced than the falling holder count suggests. One large buyer can coexist with broad caution.
Short positioning reinforces that caution. At the August 14 settlement, 4.51 million shares were sold short, equal to about 15% of the reported float and 5.36 days of average volume. The insider cluster suggests people closest to the company see value after the decline. A durable rebound still requires Ameresco to turn AI-power demand and project awards into margins, cash flow, and a balance sheet investors can underwrite without heroic ***** umptions.

#shares #power #august #amrc

Pfizer (NYSE: PFE) has faced several issues in recent years that have weighed on its share price. First, the company's coronavirus business isn't nearly as strong as it once was. Second, Pfizer is racing toward important patent cliffs, including that of Eliquis, an anticoagulant. Third, the pharmaceutical giant has faced clinical setbacks with otherwise promising pipeline candidates, including some it acquired. This problem has led to billions in impairment charges. Because of these headwinds (and others), Pfizer's shares have lagged broader equities over the past two years and have hovered below $30 apiece. Is it finally time to invest in the company? Let's see whether there is a rebound on the horizon.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's start with Pfizer's recent second-quarter update. The company's revenue increased by 1% year over year to $15 billion. While that top-line growth doesn't look impressive, it beat ***** yst estimates. On the bottom line, Pfizer's adjusted earnings per share were $0.77, slightly lower than the $0.78 reported in the prior-year quarter. Here too, Pfizer beat expectations. And it's important to highlight what drove the revenue and earnings beat.
The company noted that non-COVID revenue increased 5% year over year, while sales from launched and acquired products jumped 18%. This is great news for Pfizer. It suggests that newer (and acquired) products will help pull sales in the right direction over the medium term, while older medicines, especially within its coronavirus business, continue to lose steam.
Even with the progress Pfizer is making with relatively new launches, upcoming patent cliffs will be a major problem for the company. Consider, for instance, that Eliquis was the drugmaker's best-selling therapy during the second quarter. Pfizer's revenue from Eliquis came in at $2.4 billion, up 21% year over year. So, it arguably remains its single most important growth driver. Pfizer will have to launch more new drugs to fill the gap Eliquis will leave behind as it faces generic competition by the end of the decade. Can the company pull it off? My view is that it can.

#company #revenue #years